Please assess the completion status of the following clinical trial:

Trial Title: Anti-CD20 in Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~People may be eligible for this study if they:~* Are 18 to 70 years of age~* Agree to use a reliable method of birth control during treatment and for 6 months after treatment ends~* Have SLE (by the American College of Rheumatology criteria)~* Have had SLE for at least 6 months prior to screening~* Have active SLE disease at the screening visit~* Have organ disease (lung, stomach, intestinal, blood, kidney, and/or heart)~* Have failed standard therapy, including at least 1 immunosuppressive agent, or have experienced side effects from an immunosuppressive agent that required discontinuation of treatment~* Meet blood, liver, and kidney laboratory values set by the protocol~* Have not taken an immunosuppressive agent for 2 weeks prior to the first treatment~* Have been on a stable dose of oral corticosteroids, if taking them, for 4 weeks before the first week's visit. Oral corticosteroids may be altered as medically necessary after enrollment.~* Have at least 1 elevated autoantibody level at screening visit.~Exclusion Criteria~People will not be eligible for this study if they:~* Are pregnant or breast-feeding~* Have heart, lung, nervous system, kidney, liver, stomach, intestinal, or other diseases that may place the patient at risk if participating in the trial~* Have cranial neuropathy (a condition affecting the head region)~* Are on blood-thinning agents to prevent blood clotting~* Have a serious skin disease~* Have a certain class of heart disease~* Have had cancer, unless surgically cured basal cell carcinoma or cervical dysplasia~* Have a long term serious infectious disease such as tuberculosis or a fungal infection that is now active, or active within 2 years of the baseline visit~* Have had HIV infection or another immunosuppressive state (chemotherapy or radiation therapy)~* Have received any experimental drug within 30 days of baseline visit~* Have received any monoclonal antibody or similar medication within 3 months of the baseline visit~* Received any intravenous, joint, or muscle injection of corticosteroids within 4 weeks of the baseline visit~* Abuse alcohol or drugs~* Are unwilling or unable to follow the protocol~* Have poor veins for receiving injections.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- rituximab (Type: EXPERIMENTAL): 375 mg/m\^2 administered intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).